Northern Trust’s ChemoCentryx, Inc. CCXI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-658,607
| Closed | -$34M | – | 4769 |
|
|
2022
Q3 | $34M | Buy |
658,607
+15,839
| +2% | +$655K | 0.01% | 1111 |
|
|
2022
Q2 | $15.9M | Buy |
642,768
+86,824
| +16% | +$1.91M | ﹤0.01% | 1697 |
|
|
2022
Q1 | $13.9M | Buy |
555,944
+34,144
| +7% | +$960K | ﹤0.01% | 1929 |
|
|
2021
Q4 | $19M | Sell |
521,800
-21,978
| -4% | -$772K | ﹤0.01% | 1802 |
|
|
2021
Q3 | $9.3M | Sell |
543,778
-24,355
| -4% | -$379K | ﹤0.01% | 2329 |
|
|
2021
Q2 | $7.61M | Sell |
568,133
-571
| -0.1% | -$14.1K | ﹤0.01% | 2558 |
|
|
2021
Q1 | $29.1M | Sell |
568,704
-39,192
| -6% | -$2.36M | 0.01% | 1557 |
|
|
2020
Q4 | $37.6M | Sell |
607,896
-14,497
| -2% | -$830K | 0.01% | 1314 |
|
|
2020
Q3 | $34.1M | Buy |
622,393
+14,745
| +2% | +$794K | 0.01% | 1195 |
|
|
2020
Q2 | $35M | Buy |
607,648
+81,173
| +15% | +$4.42M | 0.01% | 1171 |
|
|
2020
Q1 | $21.2M | Buy |
526,475
+9,755
| +2% | +$414K | 0.01% | 1352 |
|
|
2019
Q4 | $20.4M | Buy |
516,720
+12,799
| +3% | +$225K | ﹤0.01% | 1704 |
|
|
2019
Q3 | $3.42M | Buy |
503,921
+146,518
| +41% | +$1.1M | ﹤0.01% | 2779 |
|
|
2019
Q2 | $3.32M | Buy |
357,403
+47,396
| +15% | +$549K | ﹤0.01% | 2781 |
|
|
2019
Q1 | $4.31M | Buy |
310,007
+10,385
| +3% | +$119K | ﹤0.01% | 2643 |
|
|
2018
Q4 | $3.27M | Sell |
299,622
-487
| -0.2% | -$5.13K | ﹤0.01% | 2763 |
|
|
2018
Q3 | $3.79M | Buy |
300,109
+36,343
| +14% | +$438K | ﹤0.01% | 2856 |
|
|
2018
Q2 | $3.47M | Sell |
263,766
-12,514
| -5% | -$150K | ﹤0.01% | 2894 |
|
|
2018
Q1 | $3.76M | Sell |
276,280
-92
| -0% | -$949 | ﹤0.01% | 2754 |
|
|
2017
Q4 | $1.64M | Buy |
276,372
+427
| +0.2% | +$2.93K | ﹤0.01% | 3233 |
|
|
2017
Q3 | $2.05M | Sell |
275,945
-928
| -0.3% | -$7.71K | ﹤0.01% | 3158 |
|
|
2017
Q2 | $2.59M | Buy |
276,873
+24,134
| +10% | +$177K | ﹤0.01% | 3009 |
|
|
2017
Q1 | $1.84M | Buy |
252,739
+5,808
| +2% | +$41.8K | ﹤0.01% | 3124 |
|
|
2016
Q4 | $1.83M | Buy |
246,931
+11,426
| +5% | +$82.3K | ﹤0.01% | 3143 |
|
|
2016
Q3 | $1.42M | Buy |
235,505
+7,832
| +3% | +$37K | ﹤0.01% | 3221 |
|
|
2016
Q2 | $1.02M | Sell |
227,673
-70,535
| -24% | -$265K | ﹤0.01% | 3340 |
|
|
2016
Q1 | $743K | Sell |
298,208
-1,235
| -0.4% | -$4.5K | ﹤0.01% | 3349 |
|
|
2015
Q4 | $2.43M | Buy |
299,443
+20,026
| +7% | +$142K | ﹤0.01% | 2944 |
|
|
2015
Q3 | $1.69M | Buy |
279,417
+18,272
| +7% | +$132K | ﹤0.01% | 3130 |
|
|
2015
Q2 | $2.15M | Buy |
261,145
+4,767
| +2% | +$37.9K | ﹤0.01% | 3019 |
|
|
2015
Q1 | $1.94M | Buy |
256,378
+2,623
| +1% | +$20.5K | ﹤0.01% | 3137 |
|
|
2014
Q4 | $1.73M | Sell |
253,755
-18,408
| -7% | -$97.3K | ﹤0.01% | 3187 |
|
|
2014
Q3 | $1.23M | Buy |
272,163
+10,846
| +4% | +$57.3K | ﹤0.01% | 3348 |
|
|
2014
Q2 | $1.53M | Sell |
261,317
-37,158
| -12% | -$209K | ﹤0.01% | 3229 |
|
|
2014
Q1 | $1.98M | Sell |
298,475
-31,723
| -10% | -$220K | ﹤0.01% | 3140 |
|
|
2013
Q4 | $1.91M | Buy |
330,198
+4,480
| +1% | +$23.1K | ﹤0.01% | 3181 |
|
|
2013
Q3 | $1.81M | Buy |
325,718
+158,680
| +95% | +$1.72M | ﹤0.01% | 3143 |
|
|
2013
Q2 | $2.36M | Buy |
+167,038
| New | +$2.16M | ﹤0.01% | 2882 |
|
Other funds holding CCXI
Northern Trust's CCXI Position: Q4 2022 in Review
Northern Trust sold out of ChemoCentryx, Inc. (CCXI) in Q4 2022, closing a stake of 658,607 shares — an estimated $34M sold.
Northern Trust first reported a position in CCXI in Q2 2013 and held it in 38 quarters. The position peaked at $37.6M in Q4 2020. 1 fund tracked by Wall St. Rank holds CCXI as of Q4 2022.
- Northern Trust reported no remaining ChemoCentryx, Inc. position as of Q4 2022 after selling out during the quarter.
- Northern Trust sold 658,607 ChemoCentryx, Inc. shares in Q4 2022, an estimated $34M.
- Northern Trust first reported a position in ChemoCentryx, Inc. in Q2 2013 and held it in 38 quarters.
- Northern Trust's ChemoCentryx, Inc. position peaked at $37.6M in Q4 2020.
- 1 fund tracked by Wall St. Rank held ChemoCentryx, Inc. as of Q4 2022.
Based on Northern Trust's 13F filing for Q4 2022, filed 13 Feb 2023.